Decoy Therapeutics Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.4M | $-2.2M | $-873.5K | $-957.8K | $-1.7M | $-972.1K | $-1.4M | $-1.7M |
| Depreciation & Amortization | — | $5.9K | — | — | $1.1K | — | — | $1.1K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $213.0K | — | — | $33.5K | — | — | $77.5K |
| Net Cash from Operating Activities | $-2.7M | $-2.9M | $-1.6M | $-862.3K | $-1.2M | $-1.4M | $-1.1M | $-1.4M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $0 | — | — | $545.6K | — | — | $-172.8K |
| Net Change in Cash | — | $-2.9M | — | — | $-636.1K | — | — | $-1.5M |
| Free Cash Flow | — | — | — | — | — | — | — | — |